Pharmeconomical analysis of the expenses connected with treatment of asthma

M. V. Ovcharuk, Y. M. Mostovoy (Vinnitsa, Ukraine)

Source: Annual Congress 2006 - Asthma - miscellaneous issues
Session: Asthma - miscellaneous issues
Session type: Electronic Poster Session
Number: 2887
Disease area: Airway diseases

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
M. V. Ovcharuk, Y. M. Mostovoy (Vinnitsa, Ukraine). Pharmeconomical analysis of the expenses connected with treatment of asthma. Eur Respir J 2006; 28: Suppl. 50, 2887

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Health care cost associated with acute and stable asthma: an economic analysis
Source: Eur Respir J 2003; 22: Suppl. 45, 418s
Year: 2003

Cost analysis for patients with severe asthma receiving omalizumab treatment
Source: International Congress 2019 – Clinical aspects of airway diseases
Year: 2019


Health care costs associated with acute asthma: a economic analysis
Source: Eur Respir J 2002; 20: Suppl. 38, 42s
Year: 2002

The cost analysis of our COPD patients
Source: Eur Respir J 2006; 28: Suppl. 50, 38s
Year: 2006

Health care claims analysis to quantify the burden of moderate-to-severe asthma
Source: Annual Congress 2012 - Looking at the cost effectiveness of asthma and COPD treatment by novel drugs and improved management
Year: 2012

A 1-day visit in a severe asthma centre: effect on asthma control, quality of life and healthcare use
Source: Eur Respir J 2016; 48: 726-733
Year: 2016



A highly complex home care service for COPD in LTOT may reduce the exacerbations and the hospitalizations
Source: Annual Congress 2011 - Exacerbations and severe chronic respiratory disease: oxygen, rehabilitation, admission to hospital and palliative care
Year: 2011


Dispensed asthma therapy and medical resource utilisation in asthma patients: results from the L777 observational study
Source: Annual Congress 2009 - Epidemiology of asthma
Year: 2009


Antibiotics prescriptions increased medical costs for COPD exacerbations.
Source: International Congress 2019 – COPD: epidemiology and spirometry
Year: 2019

An outreaching model of tertiary difficult asthma care reduces adverse asthma outcomes and healthcare utilisation costs
Source: Eur Respir J 2016; 47:1857-1860
Year: 2016


Cost of health care associated with workplace exacerbation of asthma
Source: Eur Respir J 2007; 30: Suppl. 51, 157s
Year: 2007

Persistent asthma: disease control, resource utilisation and direct costs
Source: Eur Respir J 2002; 20: 260-267
Year: 2002



Reduced cost of unscheduled healthcare resource use in patients with well controlled asthma
Source: Eur Respir J 2005; 26: Suppl. 49, 44s
Year: 2005

Difference in healthcare resource use among children with asthma who did and did not have allergic rhinitis diagnosis in a UK primary care database
Source: Eur Respir J 2002; 20: Suppl. 38, 332s
Year: 2002

Provision of self-management plans for treatment of COPD exacerbations reduce hospital admissions
Source: Eur Respir J 2007; 30: Suppl. 51, 569s
Year: 2007

Analysis of causes and quality of patients‘ treatment with often severe asthma exacerbations
Source: Eur Respir J 2007; 30: Suppl. 51, 72s
Year: 2007

Combination asthma medication and healthcare use in severe or difficult-to-treat asthma
Source: Eur Respir J 2004; 24: Suppl. 48, 131s
Year: 2004

Symptom pattern and treatment for people non-compliant with asthma medication
Source: Annual Congress 2005 - Allergic rhinitis and asthma in primary care
Year: 2005


Does long-term macrolide treatment reduce asthma exacerbations? An individual patient data meta-analysis
Source: International Congress 2019 – Clinical studies of asthma treatments
Year: 2019

Cost analysis of FeNO for asthma diagnosis in primary care in Germany.
Source: International Congress 2018 – COPD, asthma and tuberculosis: benefits related to therapy costs
Year: 2018